Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease

Sichuan Provincial People's Hospital

Status: Enrolling

Conditions: Invasive Fungal Disease

Study type: Observational

Funder types: Other

Identifiers

NCT06819410

Lunshen(Research)No.818,2024

Details and patient eligibility

About

Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease

Full description

The medical records, demographic characteristics and clinical data of patients with invasive fungal disease treated with amphotericin B or azoles were collected through the electronic medical record system of Sichuan Provincial People's Hospital from 2021 to 2024. To evaluate the efficacy and safety of these two types of drugs.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• There is no age limit, gender is not limited
• Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.

Exclusion criteria

• Patients with incomplete data or other factors affecting the clinical outcome judgement
• Patients who are judged by the investigator to be unsuitable to participate in this study.

Trial design

1,000 participants in 2 patient groups

Treatment with polyene antifungal drugs

Description:

The dosage and course of Amphotericin B or Amphotericin B cholesteryl sulphate complex were determined by clinicians, and this study was registered according to clinical practice

Treatment with azole antifungal drugs

Description:

The dosage and course of triazoles or imidazole antifungal drugs were determined by clinicians, and this study was registered according to clinical practice